Andrea T Franson
University of Michigan Rogel Cancer Center · Children's Oncology Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andrea T Franson as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:54 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06914479 · Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain TumorsUniversity of Michigan Rogel Cancer Center · recruiting · Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Malignant Brain Neoplasm, Resectable Brain Neoplasm · principal investigator
- Ph2NCT04320888 · Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialNational Cancer Institute (NCI) · active not recruiting · Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- COG NCTN Network Group Operations CenterU10CA180886 · NCI · COG RESEARCH FOUNDATION, LLC · PI Douglas S. Hawkins · fiscal years 2014 to 2026Named on NCT04320888
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:54 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed
- The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.Nat Med · 2024185 citationsRCR 24.9
- ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma.J Clin Oncol · 202598 citationsRCR 22.2
- Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial.Neuro Oncol · 202514 citationsRCR 4.0